Cooley advised Jiangsu Hengrui Pharmaceuticals on the deal. Jiangsu Hengrui Pharmaceuticals (“Hengrui”), a global pharmaceutical company focused on scientific and technological innovation, signed a global license agreement...
You must be a Standard 1 Year member to access this content.
Cooley advised Jiangsu Hengrui Pharmaceuticals on the deal. Jiangsu Hengrui Pharmaceuticals (“Hengrui”), a global pharmaceutical company focused on scientific and technological innovation, announced its strategic collaboration...
You must be a Standard 1 Year member to access this content.
Cooley advised Seven and Eight Biopharmaceuticals on the deal. Seven and Eight Biopharmaceuticals Inc. announced that it has signed an exclusive licensing agreement with Eikon Therapeutics....
You must be a Standard 1 Year member to access this content.
Cooley advised Zai Lab on the deal. Zai Lab, a research-based commercial-stage biopharmaceutical company, announced its strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics, as...
You must be a Standard 1 Year member to access this content.
Cooley advised SCYNEXIS on the deal. SCYNEXIS announced its exclusive license agreement with GSK for Brexafemme. The exclusive license agreement gives GSK rights to commercialize SCYNEXIS’ ibrexafungerp...
You must be a Standard 1 Year member to access this content.
Cooley LLP represented Structure Therapeutics, while Latham & Watkins LLP represented the underwriters in the offering. Structure Therapeutics, a clinical-stage global biopharmaceutical company, announced its $185.3 million...
You must be a Standard 1 Year member to access this content.
Cooley advised Poseida Therapeutics on the deal. Poseida Therapeutics, a clinical-stage biopharmaceutical company, announced its strategic collaboration and license agreement with Roche. The agreement will leverage Poseida’s...
You must be a Standard 1 Year member to access this content.
Cooley LLP advised Shoreline Biosciences on the deal. Shoreline Biosciences, a biotechnology company developing immunotherapies for cancer and other serious diseases, announced its worldwide strategic collaboration with...
You must be a Standard 1 Year member to access this content.
